98%
921
2 minutes
20
This study aimed to retrospectively analyze the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma (BSTS). Overall, 187 patients with BSTS in the pelvis and retroperitoneal region treated at 19 specialized sarcoma centers in Japan were included. The prognostic factors related to overall survival (OS), local control (LC), and progression-free survival (PFS) were evaluated. The 3-year OS and LC rates in the 187 patients were 71.7% and 79.1%, respectively. The 3-year PFS in 166 patients without any distant metastases at the time of primary tumor diagnosis was 48.6%. Osteosarcoma showed significantly worse OS and PFS than other sarcomas of the pelvis and retroperitoneum. In the univariate analyses, larger primary tumor size, soft tissue tumor, distant metastasis at the time of primary tumor diagnosis, P2 location, chemotherapy, and osteosarcoma were poor prognostic factors correlated with OS. Larger primary tumor size, higher age, soft tissue tumor, chemotherapy, and osteosarcoma were poor prognostic factors correlated with PFS in patients without any metastasis at the initial presentation. Larger primary tumor size was the only poor prognostic factor correlation with LC. This study has clarified the epidemiology and prognosis of patients with pelvic and retroperitoneal BSTS in Japan.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221521 | PMC |
http://dx.doi.org/10.3390/cancers14123023 | DOI Listing |
J Neurosurg Case Lessons
September 2025
Department of Neurosurgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Background: Anaplastic lymphoma kinase (ALK)-positive primary CNS anaplastic large cell lymphoma (ALCL) is an extremely rare pediatric malignancy. Its radiological appearance often mimics infectious or glial lesions, complicating diagnosis and delaying treatment.
Observations: The authors report the case of a 10-year-old immunocompetent female who presented with absence seizures and vomiting.
JMIR Cancer
September 2025
Department of Health Outcomes and Biomedical Informatics, University of Florida, 1889 Museum Road, Suite 7000, Gainesville, FL, 32611, United States, 1 352 294-5969.
Background: Disparities in cancer burden between transgender and cisgender individuals remain an underexplored area of research.
Objective: This study aimed to examine the cumulative incidence and associated risk factors for cancer and precancerous conditions among transgender individuals compared with matched cisgender individuals.
Methods: We conducted a retrospective cohort study using patient-level electronic health record (EHR) data from the University of Florida Health Integrated Data Repository between 2012 and 2023.
JMIR Med Inform
September 2025
Department of Hepatobiliary and Vascular Surgery, First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Background: Primary liver cancer, particularly hepatocellular carcinoma (HCC), poses significant clinical challenges due to late-stage diagnosis, tumor heterogeneity, and rapidly evolving therapeutic strategies. While systematic reviews and meta-analyses are essential for updating clinical guidelines, their labor-intensive nature limits timely evidence synthesis.
Objective: This study proposes an automated literature screening workflow powered by large language models (LLMs) to accelerate evidence synthesis for HCC treatment guidelines.
JCO Oncol Pract
September 2025
Princess Margaret Cancer Centre, Toronto, Canada.
Purpose: To examine associations between special education, chronic health conditions (CHCs), and college graduation in survivors of childhood cancer and their siblings.
Methods: Childhood Cancer Survivor Study participants included 23,082 5-year survivors (53.7% male; median [IQR] age at diagnosis, 6 [3-13] years; age at evaluation, 31.
PLoS One
September 2025
Department of Zoology, Baba Guru Nanak University, Nankana Sahib, Pakistan.
Secreted frizzled-related protein 4 (sFRP4) plays a fundamental role in the regulation of Wnt signalling, which is crucial for cellular proliferation and differentiation. The sFRP4 has garnered significant interest as a therapeutic target for metabolic diseases and cancer due to its mechanism of action. Although existing sFRP4 modulators show limited specificity and notable off-target effects, our study explores the potential of known bioactive compounds as more selective and less toxic alternatives.
View Article and Find Full Text PDF